Tenderwize
Retour à la recherche

Drug discount agreements from 01.07.2025 for various active ingredients under an open-house procedure

AOK NordWest - Die Gesundheitskasse·Dortmund, Germany·Deadline Apr 26, 2027 · 241 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel-Rabattverträge ab 01.07.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

30/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

30 / 100

Complexité

20 / 100

Facteurs de risque

The buyer reserves the right to conclude exclusive contracts during the term, which will suspend these open-house agree...

No guaranteed purchase volumes; actual revenue depends on prescriptions and market share.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Provide drug discount agreements for the listed active ingredients and combinations.
  • Contract duration up to 24 months from earliest start date 01.07.2025.
Afficher le résumé complet

The AOK NordWest offers drug discount agreements (Rabattverträge) under §130a Abs. 8 SGB V for multiple active ingredients via an open-house procedure. This is not a public procurement under EU directives but is published for transparency. Qualified pharmaceutical companies can join at any time until the deadline. Contracts start no earlier than 01.07.2025, with a maximum duration of 24 months. No exclusivity is granted; future exclusive contracts may suspend these agreements.

Risques

The buyer reserves the right to conclude exclusive contracts during the term, which will suspend these open-house agree...

No guaranteed purchase volumes; actual revenue depends on prescriptions and market share.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company as defined in §4 Abs. 18 AMG.
  • Must remain a pharmaceutical company for the entire contract duration.

Administrative

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; all eligible participants receive a contract.

Acheteur

Localisation

Dortmund, DEU

Site web

www.aok.de

Identifiant

DE124159739

Activité

Health

Lots (1)

LOT-0001

Drug discount agreements from 01.07.2025 for various active ingredients under an open-house procedure

Open-house procedure for drug discount agreements on multiple active ingredients (Amifampridin, Axitinib, Clindamycin & Benzoylperoxid, Fluorouracil Kombinationen, Folsäure, Imiquimod, Lamivudin & Tenofovirdisoproxil & Doravirin, Lapatinib, Macrogol, Maraviroc, Mesalazin, Peginterferon alfa-2a, Pegvisomant, Pimecrolimus, Raltegravir, Sevelamerhydrochlorid, Xylometazolin). Uniform terms and conditions. No exclusivity. Continuous accession possible.

SuppliesEU fundedElectronic submission

Localisation

Hagen, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; all eligible participants receive a contract.

Date limite

Deadline Apr 26, 2027

Détails de la procédure

Date de publication
12 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
306881-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30